1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dozens of firms to make cheap version of Merck COVID pill for poorer nations

01/20/2022 | 04:40am EDT

* Deal negotiated by U.N.-backed agency to expand output of drug

* Nearly 30 firms to sell low-cost molnupiravir in 105 nations

* Asian, African makers may sell at $20, no royalties for now

BRUSSELS, Jan 20 (Reuters) - Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck & Co's COVID-19 pill, under a landmark U.N.-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic.

Merck's early greenlight to production of its anti-viral pill molnupiravir by other companies during the pandemic is a rare example in the pharmaceutical sector, which usually protects its patented treatments for longer periods.

However, there are questions about molnupiravir which has shown low efficacy in trials and has raised concerns for side-effects, and lengthy procedures for appovals may delay supplies in many poorer nations for months.

Under the deal, negotiated by the U.N.-backed Medicines Patent Pool (MPP) with Merck, the U.S. company will not receive royalties for the sale of the low-cost version of the pill while the pandemic continues.

The MPP said the deal stipulated the pill would be distributed to 105 less-developed nations.

A molnupiravir course of 40 pills for five days is expected to cost about $20 in poorer nations, an MPP official involved in the talks with drugmakers told Reuters, citing initial estimates from drugmakers, which are subject to change.

That is far below the $700 per course the United States agreed to pay for an initial delivery of 1.7 million courses, but twice as high as first estimated by the World Health Organization (WHO)-backed programme to procure COVID-19 drugs and vaccines for the world.

The new agreement allows 27 generic drugmakers from India, China and other countries in Africa, Asia and the Middle East to produce ingredients and the finished drug.

An MPP spokesperson said deliveries from some firms covered by the deal could start as early as February. However, that will be subject to regulatory approval.

While molnupiravir is in use in the United States after approval in December, some other Western countries have cancelled or are reconsidering orders after the drug showed low efficacy in trials.

Molnupiravir has also not been approved by the World Health Organization, which makes its sale at the moment not possible in most developing countries with limited regulatory resources for national authorisations.

The drug can already be sold in India, after it received emergency approval by the national regulator, but it is not currently recommended for use because of safety risks. https://www.reuters.com/world/india/india-health-official-says-merck-covid-pill-has-major-safety-concerns-2022-01-05

NO ROYALTIES, FOR NOW

The developers of molnupiravir, which alongside Merck are U.S. firm Ridgeback Biotherapeutics and Emory University, will not receive royalties for the sale of the low-cost versions made by generic drugmakers while COVID-19 remains classified as a Public Health Emergency of International Concern by the WHO.

Bangladesh's Beximco Pharmaceuticals, India's Natco Pharma, South Africa's Aspen Pharmacare Holdings and China's Fosun Pharma are among generics firms that will produce the finished product.

Other companies, including India's Dr Reddy's Laboratories , had struck earlier deals with Merck for the production of molnupiravir. Dr Reddy's will sell molnupiravir at 1,400 rupees ($18.8) per course.

The MPP spokesperson said there was no firm estimate yet of the likely output from generics makers covered by the deal, but that poorer nations' demand was expected to be largely covered.

The MPP works to increase access to life-saving medicines for poorer countries. It also has an agreement with Pfizer for the sub-licensing of its COVID-19 pill paxlovid to generics drugmakers. (Reporting by Francesco Guarascio @fraguarascio Editing by David Goodman, Mark Potter and Susan Fenton)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASPEN PHARMACARE HOLDINGS LIMITED 1.01% 158 End-of-day quote.-29.60%
BEXIMCO PHARMACEUTICALS LIMITED -4.07% 151 End-of-day quote.-21.64%
DOW JONES AFRICA TITANS 50 INDEX -1.58% 503.45 Real-time Quote.-4.59%
DR. REDDY'S LABORATORIES LIMITED 0.10% 3908.1 End-of-day quote.-20.38%
NATCO PHARMA LIMITED -0.54% 715.15 Delayed Quote.-20.52%
PFIZER, INC. -1.79% 50.355 Delayed Quote.-13.06%
S&P AFRICA 40 INDEX -1.55% 161.87 Real-time Quote.-6.10%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 2.07% 44.37 End-of-day quote.-9.34%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
05/13Fosun Pharma Unit Gets Nod to Start Phase II Study in China of Hematologic Disorder Tre..
MT
05/11Chinese Shares Post Modest Gains; Gotion Jumps 4.5% on Argentina Deal
MT
05/11China’s Pharma Firms Post 67% Jump in Profit in 2021
MT
05/05Hangzhou Calibra Diagnostics Co., Ltd. announced that it has received CNY 220 million i..
CI
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notification letter and request form to non-registered sha..
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Form of proxy for holders of h shares for the 2022 first m..
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Form of proxy for holders of h shares for the annual gener..
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notice of 2022 first h shareholders class meeting (h share..
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notice of annual general meeting (h shares)
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Circular - annual general meeting; proposed issuance of co..
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2022 43 494 M 6 455 M 6 455 M
Net income 2022 5 095 M 756 M 756 M
Net Debt 2022 16 460 M 2 443 M 2 443 M
P/E ratio 2022 22,4x
Yield 2022 1,26%
Capitalization 105 B 15 577 M 15 577 M
EV / Sales 2022 2,79x
EV / Sales 2023 2,46x
Nbr of Employees 36 279
Free-Float 58,6%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 44,37 CNY
Average target price 55,27 CNY
Spread / Average Target 24,6%
EPS Revisions
Managers and Directors
Yi Fang Wu Chairman & Chief Executive Officer
Yu Qing Chen Co-President
Ke Xin Wang Vice Chairman & Co-President
Dong Ming Li Co-President
De Yong Wen Senior Vice President